Patents by Inventor Philip D. Gregory

Philip D. Gregory has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inactivating a glucocorticoid receptor gene in an isolated cell
    Patent number: 11884930
    Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: January 30, 2024
    Assignees: Sangamo Biosciences, Inc., City of Hope
    Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
  • METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITION
    Publication number: 20230416775
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Application
    Filed: November 7, 2022
    Publication date: December 28, 2023
    Inventors: Gregory J. Cost, Dmitry Guschin, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES
    Publication number: 20230346844
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Application
    Filed: September 12, 2022
    Publication date: November 2, 2023
    Inventors: Maria Chiara Bonini, Pietro Genovese, Philip D. Gregory, Michael C. Holmes, Luigi Naldini, David Paschon, Elena Provasi, Lei Zhang
  • DNA-binding proteins and uses thereof
    Patent number: 11661612
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 30, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Targeted integration into the PPP1R12C locus
    Patent number: 11649468
    Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 16, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Russell DeKeiver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
  • METHODS AND COMPOSITIONS FOR MODULATING PD1
    Publication number: 20220395556
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Application
    Filed: January 28, 2022
    Publication date: December 15, 2022
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • T CELL MODIFYING COMPOUNDS AND USES THEREOF
    Publication number: 20220396634
    Abstract: Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.
    Type: Application
    Filed: January 28, 2022
    Publication date: December 15, 2022
    Inventors: Philip D. Gregory, Michael C. Holmes
  • DNA-BINDING PROTEINS AND USES THEREOF
    Publication number: 20220356493
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: June 11, 2021
    Publication date: November 10, 2022
    Inventors: Philip D. GREGORY, Jeffrey C. MILLER, David PASCHON, Edward J. REBAR, Siyuan TAN, Fyodor URNOV, Lei ZHANG
  • Methods and compositions for treatment of a genetic condition
    Patent number: 11492643
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 8, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
    Patent number: 11439666
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 13, 2022
    Assignees: Sangamo Therapeutics, Inc., Ospedale San Raffaele srl
    Inventors: Maria Chiara Bonini, Pietro Genovese, Philip D. Gregory, Michael C. Holmes, Luigi Naldini, David Paschon, Elena Provasi, Lei Zhang
  • METHODS AND COMPOSITIONS FOR MODIFICATION OF HLA
    Publication number: 20220202858
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including Natural Killer (NK) cells that lack expression of one or more classic HLA genes and comprise one or more exogenous sequences that express one or more non-classic HLA gene.
    Type: Application
    Filed: July 22, 2021
    Publication date: June 30, 2022
    Inventors: Philip D. Gregory, Laurence J.N. Cooper, Hiroki Torikai
  • T cell modifying compounds and uses thereof
    Patent number: 11236175
    Abstract: Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: February 1, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes
  • Methods and compositions for modulating PD1
    Patent number: 11235026
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 1, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • METHOD OF INACTIVATING A GLUCOCORTICOID RECEPTOR GENE IN AN ISOLATED CELL
    Publication number: 20210102222
    Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 8, 2021
    Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
  • METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS
    Publication number: 20210054046
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
    Type: Application
    Filed: November 6, 2020
    Publication date: February 25, 2021
    Inventors: Trevor Collingwood, Laurence J.N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov
  • Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
    Patent number: 10918668
    Abstract: Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: February 16, 2021
    Assignees: Sangamo Therapeutics, Inc., Ospedale San Raffaele SRL
    Inventors: Philip D. Gregory, Michael C. Holmes, David Paschon, Lei Zhang, Maria Chiara Bonini, Pietro Genovese, Zulma Magnani, Sara Mastaglio, Luigi Naldini
  • Isolated human cell with an inactivated glucocorticoid receptor gene
    Patent number: 10907175
    Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: February 2, 2021
    Assignees: Sangamo Therapeutics, Inc., City of Hope
    Inventors: Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
  • Methods and compositions for modification of a HLA locus
    Patent number: 10858416
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 8, 2020
    Assignees: Sangamo Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Trevor Collingwood, Laurence J. N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov
  • Methods and compositions for treating trinucleotide repeat disorders
    Patent number: 10646543
    Abstract: Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Edward J. Rebar, H. Steve Zhang
  • NOVEL DNA-BINDING PROTEINS AND USES THEREOF
    Publication number: 20190169640
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: February 12, 2019
    Publication date: June 6, 2019
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang